| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,235 |
1,738 |
$87K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
773 |
731 |
$46K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
234 |
234 |
$23K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
199 |
174 |
$8K |
| 72275 |
|
145 |
129 |
$8K |
| 76942 |
|
187 |
156 |
$7K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
36 |
31 |
$2K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
629 |
553 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
660 |
594 |
$759.16 |
| 20553 |
|
14 |
14 |
$458.59 |
| 20552 |
|
13 |
13 |
$429.50 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
33 |
28 |
$217.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
132 |
115 |
$23.46 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
39 |
39 |
$8.18 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
265 |
246 |
$0.51 |